Alan S. Go, MD

Articles

November 30th 2015

Anticoagulation in Atrial Fibrillation: Impact of Mental Illness

Susan K. Schmitt, PhD Mintu P. Turakhia, MD, MAS Ciaran S. Phibbs, PhD Rudolf H. Moos, PhD Dan Berlowitz, MD, MPH Paul Heidenreich, MD, MS Victor Y. Chiu, MD Alan S. Go, MD Sarah A. Friedman, MSPH Claire T. Than, MPH Susan M. Frayne, MD, MPH

Atrial fibrillation patients with mental health conditions are less likely to be eligible for warfarin receipt, and those who are eligible receive warfarin at lower rates.

November 7th 2011

Ethnic Differences in the Development of Albuminuria: The DISTANCE Study

Andy I. Choi, MD, MAS Andrew J. Karter, PhD Jennifer Y. Liu, MPH Bessie A. Young, MD, MPH Alan S. Go, MD Dean Schillinger, MD

Despite uniform access to medical care, Filipinos, blacks, and Asians with diabetes developed albuminuria at higher rates than whites.

September 6th 2011

Mental Illness and Warfarin Use in Atrial Fibrillation

Graham A. Walker, MD Paul A. Heidenreich, MD, MS Ciaran S. Phibbs, PhD Alan S. Go, MD Victor Y. Chiu, BA Susan K. Schmitt, PhD Lakshmi Ananth, MS Susan M. Frayne, MD, MPH

Atrial fibrillation patients with mental illness are less likely to receive warfarin anticoagulation; those who do receive warfarin have excess risk of over-anticoagulation.

November 1st 2007

Glycemic Response to Newly Initiated Diabetes Therapies

Andrew J. Karter, PhD Howard H. Moffet, MPH Jennifer Liu, MPH Melissa M. Parker, MS Ameena T. Ahmed, MD Alan S. Go, MD Joe V. Selby, MD

April 1st 2004

Efficacy of Anticoagulation for Stroke Prevention and Risk Stratification in Atrial Fibrillation: Translating Trials into Clinical Practice

Alan S. Go, MD